Alzheimer's Blood Tests: What Pharmacists Need to Know

Plasma p-tau217 blood tests can identify Alzheimer's disease pathology with accuracy approaching PET and CSF, but they detect amyloid status, not cognitive decline. Current guidelines restrict their use to specialty settings with objective cognitive impairment, yet direct-to-consumer tests and primary care ordering are already outpacing the evidence. Pharmacists should be prepared to counsel patients on what these results do and do not mean, flag false-positive risk in patients with severe renal impairment (eGFR 30 or below), and understand that a positive result does not equal a dementia diagnosis.

Source	Key finding	Grade / Verdict
Automated Plasma p-tau217 Accurately Detects Alzheimer Pathology Across Care Settings Study · Nature Medicine foundation study Validated the fully automated Lumipulse p-tau217 assay in 1,767 patients across Sweden, Spain, and Italy, proving the test matches PET/CSF accuracy in real-world clinical settings.	AUC 0.93-0.96 across primary and specialty care	Grade: High Practice-changing
Plasma p-tau217 Clocks Estimate Timing of Alzheimer Symptom Onset Study · Nature Medicine prediction model Introduced clock models using plasma p-tau217 to estimate when cognitively normal individuals will develop AD symptoms, with markedly shorter lead times in older adults.	Median prediction error of 3.0-3.7 years for symptom onset	Grade: Moderate Hypothesis-generating
Blood Biomarker Guideline Sets Accuracy Thresholds for Alzheimer's Workup Study · Alzheimer's & Dementia clinical guideline First Alzheimer's Association CPG for blood-based biomarkers, restricting endorsed use to specialty care after comprehensive evaluation and flagging CKD and neprilysin inhibitors as confounders.	90% sensitivity / 75% specificity minimum for triaging use	Grade: Low Confirmatory
Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic Study · Journal of Alzheimer's Disease real-world safety signal Confirmed excellent diagnostic accuracy (AUC 0.944-0.984) in a real-world early-onset AD cohort but identified severe renal dysfunction as a source of false-positive p-tau217 results.	False positives in patients with eGFR 30 or below	Grade: Low Confirmatory
Rational Use of Blood Biomarkers in Alzheimer's Diagnosis Study · Journal of the American Geriatrics Society critical counterpoint Argues for diagnostic restraint: current tests detect amyloid, not cognitive decline, and widespread use in low-prevalence populations generates false positives, patient distress, and overtreatment risk.	BBMs correlate with amyloid PET, not tau PET or cognition	Grade: Low Confirmatory

Alzheimer's p-tau217 blood biomarker dementia direct-to-consumer clinical guideline patient counseling CKD anti-amyloid therapy

🎓

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.